Aarti Pharmalabs (NSE:AARTIPHARM) Inventories, Finished Goods: ₹0 Mil (As of Mar. 2026)


NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
57 GF Score
Price ₹709.45
GF Value ₹643.46
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Inventories, Finished Goods?

Aarti Pharmalabs NSE:AARTIPHARM +0.92% 57 Inventories, Finished Goods is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 57/100 and a GF Value™ of ₹643.46 (Fairly Valued). The stock has 3 warning signs investors should review.

Aarti Pharmalabs's annual finished goods declined from Mar. 2024 (₹2,966 Mil) to Mar. 2025 (₹2,310 Mil) and declined from Mar. 2025 (₹2,310 Mil) to Mar. 2026 (₹0 Mil).

Aarti Pharmalabs Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Aarti Pharmalabs's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Pharmalabs Inventories, Finished Goods Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Inventories, Finished Goods
Get a 7-Day Free Trial 1,902.18 2,653.11 2,966.47 2,310.46 0.00

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,310.46 0.00 0.00 0.00 0.00
NSE:AARTIPHARM
57GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Pharmalabs Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of ₹0 Mil mean?
Aarti Pharmalabs (NSE:AARTIPHARM) has a Inventories, Finished Goods of ₹0 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Aarti Pharmalabs and its competitors.
Is Aarti Pharmalabs' Inventories, Finished Goods too high?
Aarti Pharmalabs' current Inventories, Finished Goods is ₹0 Mil. Overall, Aarti Pharmalabs has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Inventories, Finished Goods compare to ZTS and UTHR?
Aarti Pharmalabs' Inventories, Finished Goods of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Aarti Pharmalabs and its competitors. Aarti Pharmalabs's current Inventories, Finished Goods is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹643.46, compared to a current price of ₹709.45 — trading 10.3% above its estimated fair value. The current Inventories, Finished Goods is ₹0 Mil. Aarti Pharmalabs' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current Inventories, Finished Goods is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹709.45 is trading 10.3% above its estimated GF Value™ of ₹643.46. GuruFocus considers Aarti Pharmalabs to be Fairly Valued.

Key valuation signals for NSE:AARTIPHARM:

  • Inventories, Finished Goods: ₹0 Mil
  • GF Value™: ₹643.46 vs. price of ₹709.45 (10.3% above fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
57GF Score

Get the complete analysis for NSE:AARTIPHARM

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹709.45
Price
₹643.46
GF Value